https://www.selleckchem.com/products/aunp-12.html
03). Time to discharge from ED in the TXA group was significantly lower than the PANP group (p0.001) The absolute risk reduction (ARR), relative risk reduction, and number needed to harm of treatment with TXA for anterior nasal bleeding were 14.00% (95%CI 1.11 - 26.89), 17.50% (95%CI 0.60 - 37.27), and 7.14 (95%CI 3.71 -90.43), respectively. Topical TXA is an appropriate treatment option in bleeding cessation, and reducing re-bleeding and duration of hospital stay in patients with epistaxis who take antiplatelet agents. Topical TXA
Curtir
Comentario
Compartilhar
